Incidence and clinical outcome of cytomegalovirus infection in recipients of allogenic haematopoietic stem cell transplantation; experience from a tertiary care hospital in Pakistan
DOI:
https://doi.org/10.61529/idjp.v33i4.292Abstract
Background: Infectious complications are a major factor affecting the prognosis of HSCT recipients. Cytomegalovirus is responsible for substantial mortality in post-transplant patients. The objective of our study was to assess the frequency and outcomes of CMV infection in patients undergoing hematopoietic stem cell transplant.
Material and Methods: This retrospective study was conducted at the Aga Khan University Karachi, from January 2015 to December 2021. Quantitative PCR was done to detect CMV infection. Survival analysis was performed using the Kaplan-Meier method. Cox regression was employed to assess factors affecting survival.
Results: We included 112 patients. The frequency of CMV infection in the transplant period was 52%, with 97% of cases occurring within the first 100 days. CMV infection within 30 days occurred in 57%, between 30 and 100 days in 38% and after 100 days in 5% of patients. CMV PCR positive patients had a mean survival of 43 months (95% CI: 31.3-55.2), while CMV PCR negative patients showed an estimated mean survival of 70 months. Cox regression showed CMV positive adults with GVHD had a lower mean survival. CMV status (HR: 2.2, p-value: 0.04) and ATG use (HR: 2.3, p-value: 0.04) were associated with an increased hazard of death. No other variables were significant.
Conclusion: Overall frequency of CMV infection in our study was 52% with the majority occurring within 100 days of transplant. Adults with GVHD and patients receiving ATG had a decreased mean survival time. Understanding of factors worsening the prognosis of CMV infection is important to improve clinical practice.
Keywords: Cytomegalovirus, Allogenic stem cell transplantation, ATG, GVHD
References
Pande A, Dubberke ER. Cytomegalovirus infections of the stem cell transplant recipient and hematologic malignancy patient. Infect Dis Clin North Am. 2019; 33(2): 485–500. DOI: https://doi.org/10.1016/j.idc.2019.02.008
Ljungman P, De La Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019; 19(8): e260–72. DOI: https://doi.org/10.1016/s1473-3099(19)30107-0
Giménez E, Torres I, Albert E, Piñana JL, Hernández-Boluda JC, Solano C, et al. Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. Am J Transplant. 2019; 19(9): 2479–94. DOI: https://doi.org/10.1111/ajt.15515
Zavras P, Su Y, Fang J, Stern A, Gupta N, Tang Y, et al. Impact of preemptive therapy for cytomegalovirus on toxicities after allogeneic hematopoietic cell transplantation in clinical practice: A retrospective single-center cohort study. Biol Blood Marrow Transplant. 2020; 26(8): 1482–91. DOI: https://doi.org/10.1016/j.bbmt.2020.03.019
Meng XY, Fu HX, Zhu XL, Wang JZ, Liu X, Yan CH, et al. Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. Ann Hematol. 2020; 99(11): 2659–70. DOI: https://doi.org/10.1007/s00277-020-04201-4
Christopeit M, Schmidt-Hieber M, Sprute R, Buchheidt D, Hentrich M, Karthaus M, et al. Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2021; 100(2): 321–36. DOI: https://doi.org/10.1007/s00277-020-04297-8
Rojas-Rechy MH, Gaytán-Morales F, Sánchez-Ponce Y, Castorena-Villa I, López-Martínez B, Parra-Ortega I, et al. Herpesvirus screening in childhood hematopoietic transplant reveals high systemic inflammation in episodes of multiple viral detection and an EBV association with elevated IL-1β, IL-8 and graft-versus-host disease. Microorganisms. 2022 Aug 22;10(8):1685. DOI: https://doi.org/10.3390/microorganisms10081685
Passweg JR, Baldomero H, Ciceri F, Corbacioglu S, De La Cámara R, Dolstra H, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplant. 2023; 58(6): 647–58. DOI: https://doi.org/10.1038/s41409-023-01943-3
González‐Cruz C, Repiso T, Ferrándiz‐Pulido C, Navarro A, García‐Patos V. Risk factors and clinical characteristics of acute and chronic cutaneous graft‐versus‐host disease in pediatric patients undergoing hematopoietic stem cell transplantation. Pediatr Dermatol. 2023; 40(6): 1077–80. DOI: https://doi.org/10.1111/pde.15447
Sulaiman NY, Anuar NA, Arshad N, Cheong CS, Liong CC, Khairullah S, et al. CMV infection post allogeneic hematopoietic stem cell transplantation in a resource limited country. Indian J Hematol Blood Transfus. 2023; 40; 97-102. DOI: https://doi.org/10.1007/s12288-023-01655-0
Moghnieh R, Tamim H, Abyad A, Jadayel M, Awad L, Abdallah D, et al. Pre-engraftment infectious complications and patient outcomes after allogeneic hematopoietic cell transplantation: a single-center experience from Lebanon. Infection. 2020; 48(3): 385–401. DOI: https://doi.org/10.1007/s15010-020-01407-6
Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013; 122(19): 3359–64. DOI: https://doi.org/10.1182/blood-2013-05-499830
Shafat MS, Mehra V, Peggs KS, Roddie C. Cellular therapeutic approaches to cytomegalovirus infection following allogeneic stem cell transplantation. Front Immunol. 2020; 11: 1694. DOI: https://doi.org/10.3389/fimmu.2020.01694
Stern A, Papanicolaou GA. CMV Prevention and Treatment in Transplantation: What’s New in 2019. Curr Infect Dis Rep. 2019 Nov;21(11):45. DOI: https://doi.org/10.1007/s11908-019-0699-0
Esquirol A, Pascual MJ, Kwon M, Pérez A, Parody R, Ferra C, et al. Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021; 56(10): 2432–44. DOI: https://doi.org/10.1038/s41409-021-01328-4
Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, et al. Incidence, risk factors and outcome of pre-engraftment gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: An Italian prospective multicenter survey. Clin Infect Dis. 2017; 65(11):1884–96. DOI: https://doi.org/10.1093/cid/cix690
Chen W, Zhao Y, Luo Y, Yu J, Fu H, Lai X, et al. Clinical characteristics, microbiology, and risk factors for mortality of pre-engraftment and post-engraftment bloodstream infection in hematopoietic stem cell Transplantation Recipients. Infect Drug Resist. 2022; 15: 6893–905. DOI: https://doi.org/10.2147/idr.s392804
Bittencourt MCB, Ciurea SO. Recent advances in allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2020; 26(9): e215–21. DOI: https://doi.org/10.1016/j.bbmt.2020.06.007
Yanada M, Konuma T, Yamasaki S, Kondo T, Fukuda T, Shingai N, et al. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: Clinical features and outcomes. Bone Marrow Transplant. 2021; 56(5): 1126–33. DOI: https://doi.org/10.1038/s41409-020-01163-z
Gifford G, Sim J, Horne A, Ma D. Health status, late effects and long‐term survivorship of allogeneic bone marrow transplantation: A retrospective study. Intern Med J. 2014; 44(2): 139–47. DOI: https://doi.org/10.1111/imj.12336
Iftikhar R, Farhan M, Khan M, Chaudhry QUN, Ghafoor T, Shahbaz N, et al. Cytomegalovirus infection post-allogeneic stem cell transplantation: Experience from a country with high seropositivity. Transplant Cell Ther. 2023; 29(8): 521.e1-521.e7. DOI: https://doi.org/10.1016/j.jtct.2023.04.023
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017; 377(25): 2433–44.
DOI: https://doi.org/10.1056/nejmoa1706640
Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, et al. Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation. N Engl J Med. 2014; 370(19): 1781–9. DOI: https://doi.org/10.1056/nejmoa1309533
Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A randomized trial. Ann Intern Med. 2015; 162(1): 1–10. DOI: https://doi.org/10.7326/m13-2729
Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: A retrospective cohort study. Lancet Haematol. 2016; 3(3): e119–27. DOI: https://doi.org/10.1016/s2352-3026(15)00289-6
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010; 363(22): 2091–101. DOI: https://doi.org/10.1056/nejmoa1004383
Wu JL, Ma HY, Lu CY, Chen JM, Lee PI, Jou ST, et al. Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients. J Microbiol Immunol Infect. 2017 Jun;50(3):307–13.
DOI: https://doi.org/10.1016/j.jmii.2015.07.011
Rastogi S, Ricci A, Jin Z, Bhatia M, George D, Garvin JH, et al. Clinical and economic impact of cytomegalovirus infection among children undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019; 25(6): 1253–9. DOI: https://doi.org/10.1016/j.bbmt.2018.11.028
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Zurrya Khan, Nabiha Saeed, Dahir Ashfaq, hamza Jehanzeb, Usman Shaikh, Zehra Fadoo, Salman adil, Munira moosajee, Reyan Hussain Shaikh, Mashal Waqas, tayyaba Muneer, Maria Ali, Natasha Ali

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.